

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 October 2001 (25.10.2001)

PCT

(10) International Publication Number
WO 01/78694 A2

(51) International Patent Classification⁷: A61K 9/72, 9/14

Beechen Cliff Road, Bath BA2 4QR (GB). **GILL, Rajbir**

(21) International Application Number: PCT/GB01/01732

[GB/GB]; 7 Oak Tree Close, Trowbridge, Wiltshire BA14

(22) International Filing Date: 17 April 2001 (17.04.2001)

9BD (GB). **BRAMBILLA, Gaetano** [IT/IT]; Via Palermo,

(25) Filing Language: English

26/A, I-43100 Parma (IT). **MUSA, Rossella** [IT/IT]; Via

(26) Publication Language: English

Palermo, 26/A, I-43100 PARMA (IT). **FERRARINI,**

(30) Priority Data:

Lorenzo [IT/IT]; Via Palermo, 26/A, I-43100 PARMA

0009469.8 17 April 2000 (17.04.2000) GB
00113608.4 27 June 2000 (27.06.2000) EP

(IT).

(71) Applicant (for all designated States except US): VECTURA LIMITED [GB/GB]; 12 St. James's Square, London SW1Y 4RB (GB).

(74) Agents: HUMPHREYS, Ceris, Anne et al.; Abel & Imray, 20 Red Lion Street, London WC1R 4PQ (GB).

(72) Inventors; and

(81) Designated States (national): AE, AG, AL, AM, AT, AU,

(75) Inventors/Applicants (for US only): STANIFORTH, John, Nicholas [GB/GB]; High Trees, 170 Bloomfield Road, Bath BA2 2ST (GB). MORTON, David, Alexander, Vodden [GB/GB]; Linsley House, 2nd Floor Flat,



AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

[Continued on next page]

(54) Title: IMPROVEMENTS IN OR RELATING TO FORMULATIONS FOR USE IN INHALER DEVICES



WO 01/78694 A2

(57) Abstract: A formulation for an inhaler device comprises carrier particles having a diameter of at least 50 μm and a mass median diameter of at least 175 μm ; active particles; and additive material to which is able to promote release of the active particles from the carrier particles on actuation of the inhaler device. The formulation has excellent flowability even at relatively high fine particle contents.

BEST AVAILABLE COPY



IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*

Improvements in or relating to formulations
for use in inhaler devices

The invention relates to carrier materials for use in
5 inhaler devices, to formulations comprising the carrier
materials and to the use of the formulations.

The administration of pharmacologically active agents
by inhalation is a widely used technique, especially for
the treatment of diseases of the respiratory tract. The
10 technique is also used for the administration of certain
active agents having systemic action, which are absorbed,
via the lungs, into the bloodstream. Known inhaler devices
include nebulizers, pressurised metered dose inhalers and
dry powder inhalers. The present invention is primarily
15 concerned with formulations for use in dry powder inhalers,
although in some circumstances formulations according to
this invention may also or instead be useful in pressurised
metered dose inhalers.

The delivery of dry powder particles of an active
20 agent to the respiratory tract presents certain problems.
The inhaler should deliver to the lungs the maximum
possible proportion of the active particles expelled from
the device, including a significant proportion to the lower
lung, preferably even at the poor inhalation capabilities
25 of some patients, especially asthmatics. In use of many of
the currently available devices, however, only a
proportion, and frequently as little as 10%, of the active
particles expelled from the device on inhalation reach the
lower lung.

On exit from the inhaler device, the active particles should form a physically and chemically stable aerocolloid which remains in suspension until it reaches an alveolar or other absorption site. Once at the absorption site, the 5 active particles should be capable of efficient collection by the pulmonary mucosa with no active particles being exhaled from the absorption site.

The size of the active particles is important. For effective delivery of active particles deep into the lungs, 10 the active particles should be small, with an equivalent aerodynamic diameter substantially in the range of up to 10 μm . Small particles are however thermodynamically unstable due to their high surface area to volume ratio, which provides significant excess surface free energy and 15 encourages particles to agglomerate. Agglomeration of small particles in the inhaler and adherence of particles to the walls of the inhaler can result in the active particles leaving the inhaler as large agglomerates or in their not leaving the inhaler and remaining adhered to the 20 interior thereof.

The uncertainty as to the extent of agglomeration of the particles between each actuation of the inhaler and between different inhalers and different batches of particles, leads to poor dose reproducibility. It has been 25 found that powders are generally reproducibly fluidisable, and therefore reliably removable from an inhaler device, when the particles have a diameter greater than 60 μm . Good flow properties are desirable in the contexts of metering and of dispersal from the device.

To give the most effective dry powder aerosol, therefore, the particles should be large while in the inhalers, but small when in the respiratory tract.

It is common, in an attempt to achieve those demands, 5 to include in the dry powder formulation carrier particles, to which the active particles can adhere whilst in the device, the active particles then being dispersed from the surfaces of the carrier particles on inhalation into the respiratory tract, to give a fine suspension. It is known 10 that the presence of a certain amount of fine excipient material, normally of the same material as the carrier, can improve the proportion of drug reaching the lung. The presence of such a fraction of fine excipient is conventionally limited to less than 10% and generally less 15 than 5% due to the catastrophic loss of flowability at higher fine particle contents, leading to poor dose reproducibility.

The proportion of the active particles reaching the lung can be increased by incorporating in the formulation 20 an agent which promotes release of the active particle, as described in WO96/23485.

The invention provides a formulation for use in an inhaler device, comprising
carrier particles having a diameter of at least 50 μ m
25 and a mass median diameter of at least 175 μ m;
active particles; and
additive material which is able to promote release of
the active particles from the carrier particles on
actuation of the inhaler device.

The formulation of the invention surprisingly has both excellent flowability within the device and, on expulsion from the device, permits good dispersion of the active particles from the carrier particles and generation of a 5 relatively high fine particle fraction, promoting delivery of a relatively large proportion of the active particles into the lung.

The use of carrier particles of relatively large size is described in WO96/02231, but that document does not 10 suggest the incorporation of additive material to promote release of the active particles from the carrier particles. The carrier particles used in accordance with the present invention have a mass median diameter (MMD) of at least 175 μm . In fact, it is preferred that the MMD of the 15 carrier particles is at least 200 μm , and more preferably at least 250 μm .

The carrier particles have a diameter of at least 50 μm . Although as described below the formulation may include particles of diameter less than 50 μm of the same 20 material as the carrier particles, those smaller particles are not included within the term "carrier particles" as used herein. Advantageously, not more than 10% by weight, and preferably not more than 5% by weight, of the carrier particles have a diameter of 150 μm or less. Advantageously 25 at least 90% by weight of the carrier particles have a diameter of 175 μm or more, and preferably 200 μm or more. Advantageously, at least 90% by weight, and preferably at least 95% by weight, of the carrier particles have a diameter of not more than 1mm. Preferably at least 90% by 30 weight of the carrier particles have a diameter of not more

than 600 μm . Advantageously, at least 50% by weight, and preferably at least 60% by weight, of the carrier particles have a diameter of 200 μm or more. Preferably, at least 90% by weight of the carrier particles have a diameter between 5 150 μm and 750 μm , more preferably between 150 μm and 650 μm . Particular advantages are offered by formulations in which substantially all of the carrier particles have a diameter in the range of about 210 to about 360 μm or from about 350 to about 600 μm .

10 The carrier particles may be of any acceptable pharmacologically inert material or combination of materials. For example, the carrier particles may be composed of one or more materials selected from sugar alcohols; polyols; for example sorbitol, mannitol and 15 xylitol, and crystalline sugars, including monosaccharides and disaccharides; inorganic salts such as sodium chloride and calcium carbonate; organic salts such as sodium lactate; and other organic compounds such as urea, polysaccharides, for example starch and its derivatives; 20 oligosaccharides, for example cyclodextrins and dextrans. Advantageously the carrier particles are of a crystalline sugar, for example, a monosaccharide such as glucose or arabinose, or a disaccharide such as maltose, saccharose, dextrose or lactose. Preferably, the carrier particles are 25 of lactose.

The carrier particles are preferably of a material having a fissured surface, that is, on which there are clefts and valleys and other recessed regions, referred to herein collectively as fissures. The fissures should 30 preferably be at least 5 μm wide extending to at least 5 μm

deep, preferably at least 10 μm wide and 10 μm deep and most preferably at least 20 μm wide and 20 μm deep.

Because of the excellent flow properties of the formulations containing the fissured carrier particles, the 5 formulations offer special advantages in the administration of active agents to be administered in relatively large doses. Thus, whereas formulations containing conventional lactose carriers and fine particle contents of above 5% tend to have poor flow properties, with flow properties at 10 fine particle contents above 10% being very poor, the formulations of the invention may have adequate flow properties even at fines contents (that is contents of active particles and of any fine particles of additive material, together with any other particles of aerodynamic 15 diameter of not more than 20 μm) of up to 90% by weight, based on the total weight of fines and carrier particles. Moreover, the fissured carrier particles offer particular 20 advantages in that they are capable of retaining relatively large amounts of fine material in the fissures without or with only little segregation. That is thought to underly the good respirable fraction that is generated in use of the formulations and is especially advantageous in use of the carrier particles with certain additive materials, for example, magnesium stearate, which tend to cause 25 segregation of the components, permitting increased amounts of such additive materials to be used without increasing segregation to unacceptable levels. Advantageously, the fines content is not more than 50% by weight, and more preferably not more than 20% by weight, based on the total 30 weight of fines and carrier particles. Preferably, the

fines content is at least 5% by weight, based on the total weight of fines and carrier particles. The invention offers particular advantages in the case of formulations containing at least 10%, for example, from 10 to 20% by 5 weight fines or at least 20%, for example from 20 to 50% by weight fines, in each case, based on the total weight of fines and carrier particles. The fines content may include from 0.1 to 99% by weight active particles, for example from 0.1 to 90% by weight, and advantageously from 0.1 to 10 80% by weight active particles, in each case based on the total weight of fines. In many cases, however, the active particles will constitute less than half of the total weight of fines.

A number of methods may be used to determine whether 15 carrier particles have a fissured surface that will offer the above-mentioned capability of retaining relatively large fines contents substantially without segregation:

1. Determination of tapped density.

The tapped density of the fissured carrier particles 20 may be about 6% or more, and preferably 15% or more, lower than the tapped density of carrier particles of the same material and of particle characteristics of a kind typical of carrier particles which have conventionally been used in the manufacture of inhalable powders. In the case of 25 fissured carrier particles of crystalline sugars, for example lactose, the tapped density of the fissured particles is not more than 0.75g/cm³, and preferably not more than 0.70g/cm³. The tapped density of lactose grades conventionally used in the manufacture of commercial DPI

formulations is typically about 0.8g/cm³. Tapped densities referred to herein may be measured as follows:

A measuring cylinder is weighed on a top pan balance (2 place). Approximately 50g powder is introduced into the 5 measuring cylinder, and the weight is recorded. The measuring cylinder containing the powder is attached to a jolting volumeter (Jel Stampfvolumeter). The jolting volumeter is set to tap 200 times. During each tap, the measuring cylinder is raised and allowed to fall a set 10 distance. After the 200 taps, the volume of the powder is measured. The tapping is repeated and the new volume measured. The tapping is continued until the powder will settle no more. The tapped density is calculated as the weight of the powder divided by the final tap volume. The 15 procedure is performed three times (with new powder each time) for each powder measured, and the mean tapped density calculated from those three final tapped volume values.

2. Mercury Intrusion Porosimetry. Mercury intrusion porosimetry assesses the pore size distribution and the 20 nature of the surface and pore structure of the particles. Porosimetry data is suitably collected over pressure range 3.2kPa to 8.7MPa, for example, using an Autopore 9200 II 25 Porosimeter (Micromeritics, Norcross, USA). Samples should be evacuated to below 5Pa prior to analysis to remove air and loosely bound surface water. Suitable lactose is characterised by a bulk density of not more than 0.65g/cm³ and preferably not more than 0.6g/cm³. Suitable lactose is also characterised by a total intrusion volume measured by mercury intrusion porosimetry of at least 0.8cm³g⁻¹ and 30 preferably at least 0.9cm³g⁻¹. (It has been found that

lactose having a bulk density of 0.6g/cm³ as measured by mercury intrusion porosimetry has a tapped density of about 0.7g/cm³, whereas the discrepancy between the two methods at lower densities is less.)

5 3. "Fissure Index". The term "fissure index" used herein refers to the ratio of a theoretical envelope volume of the particles, as calculated from the envelope of the particles, to the actual volume of the particles, that is, omitting fissures within the envelope. Suitable particles
10 are those having a fissure index of at least 1.25. The theoretical envelope volume may be determined optically, for example, by examining a small sample of the particles using an electron microscope. The theoretical envelope volume of the particles may be estimated via the following
15 method. An electron micrograph of the sample may be divided into a number of grid squares of approximately equal populations, each containing a representative sample of the particles. The population of one or more grids may then be examined and the envelope encompassing each of the
20 particles determined visually as follows. The Feret's diameter for particles within a grid is measured relative to a fixed axis of the image. Typically at least ten particles are measured for their Feret's diameter. Feret's diameter is defined as the length of the projection of a
25 particle along a given reference line as the distance between the extreme left and right tangents that are perpendicular to the reference line. A mean Feret's diameter is derived. A theoretical mean envelope volume may then be calculated from this mean diameter to give a
30 representative value for all the grid squares and thus the

whole sample. Division of that value by the number of particles gives the mean value per particle. The actual volume of the particles may then be calculated as follows. First, the mean mass of a particle is calculated. A sample 5 of approximately 50mg is taken and its precise weight recorded to 0.1mg. Then by optical microscopy the precise number of particles in that sample is determined. The mean mass of one particle can then be determined. The procedure is then repeated five times to obtain a mean value of this 10 mean. Second, a fixed mass of particles (typically 50g), is weighed out accurately, and the number of particles within this mass is calculated using the above mean mass value of one particle. Finally, the sample of particles is immersed in a liquid in which the particles are insoluble 15 and, after agitation to remove trapped air, the amount of liquid displaced is measured. From this the mean actual volume of one particle can be calculated. The fissure index is advantageously not less than 1.5, and is, for example, 2 or more.

20 4. "Rugosity Coefficient". The rugosity coefficient is used to mean the ratio of the perimeter of a particle outline to the perimeter of the 'convex hull'. This measure has been used to express the lack of smoothness in the particle outline. The 'convex hull' is defined as a 25 minimum enveloping boundary fitted to a particle outline that is nowhere concave. (See "The Shape of Powder-Particle Outlines" A. E. Hawkins, Wiley.) The 'rugosity coefficient' may be calculated optically as follows. A sample of particles should be identified from an electron 30 micrograph as identified above. For each particle the

perimeter of the particle outline and the associated perimeter of the 'convex hull' is measured to provide the rugosity coefficient. This should be repeated for at least ten particles to obtain a mean value. The mean rugosity 5 coefficient is at least 1.25.

Carrier particles which have the above-mentioned capability of retaining relatively large amounts of fine material without or with only little segregation will generally comply with all of Methods 1 to 4 above, but for 10 the avoidance of doubt any carrier particles which comply with at least one of Methods 1 to 4 is deemed to be a fissured particle.

The carrier particles are advantageously in the form of an agglomerate consisting of a plurality of crystals 15 fused to one another, the fastness of agglomeration being such that the carrier particles have substantially no tendency to disintegrate on expulsion from the inhaler device. In the case of crystalline sugars, such as lactose, such structures may be obtained in a wet 20 granulation process, in which crystals within an agglomerate become fused to one another by solid bridges, the resultant structure having a complex shape of high irregularity and/or high fractal dimension, including a multiplicity of clefts and valleys, which in some cases may 25 be relatively deep. Each agglomerate will generally contain at least three lactose primary crystals of the characteristic tomahawk shape.

Such agglomerates are clearly distinguished from agglomerates of the kind which form in powder formulations

by aggregation of particles, which do tend to disintegrate on expulsion from the inhaler.

Suitably shaped carrier particles also include dendritic spherulites of the type disclosed in US 4349542
5 for use in tablet manufacture.

The carrier particles advantageously constitute at least 50%, preferably at least 60% and especially at least 70% by weight of the formulation, based on the total weight of the formulation.

10 The additive material, which is preferably on the surfaces of the carrier particles, promotes the release of the active particles from the carrier particles on actuation of the inhaler device. The formulation containing the additive material should, however, be such
15 that the active particles are not liable to be released from the carrier particles before actuation of the inhaler device. The additive material, which it will be appreciated is of a different material from the carrier particles, may be in the form of particles, the additive
20 particles being attached to the surfaces of the carrier particles.

In International Specification WO 96/23485 many examples are given of additive materials which are such that the active particles are not liable to be released
25 from the carrier particles before actuation of the inhaler device but are released during use of the inhaler device. "Actuation of the inhaler device" refers to the process during which a dose of the powder is removed from its rest position in the inhaler device, usually by a patient

inhaling. That step takes place after the powder has been loaded into the inhaler device ready for use.

If it is desired to test whether or not the active particles of a powder are liable to be released from the 5 carrier particles before actuation of the inhaler device a test can be carried out. A suitable test is described in International Specification WO96/23485 (Example 12 and 13). A powder whose post-vibration homogeneity measured as a percentage coefficient of variation, after being subjected 10 to the described test, is less than about 5% can be regarded as acceptable.

It is believed that additive material is attracted to and adheres to high energy sites on the surfaces of the carrier particles. On introduction of the active 15 particles, many of the high energy sites are now occupied, and the active particles therefore occupy the lower energy sites on the surfaces of the carrier particles. That results in the easier and more efficient release of the active particles in the air stream created on inhalation, 20 thereby giving increased deposition of the active particles in the lungs.

However, as indicated above, it has been found that the addition of more than a small amount of additive material can be disadvantageous because of the adverse 25 effect on the ability to process the mix during commercial manufacture.

It is also advantageous for as little as possible of the additive material to reach the lungs on inhalation of the powder. Although the additive material will most 30 advantageously be one that is safe to inhale into the

lungs, it is still preferred that only a very small proportion, if any, of the additive material reaches the lung, in particular the lower lung. The considerations that apply when selecting the additive material and other 5 features of the powder are therefore different from the considerations when a third component is added to carrier and active material for certain other reasons, for example to improve absorption of the active material in the lung, in which case it would of course be advantageous for as 10 much as possible of the additive material in the powder to reach the lung.

The optimum amount of additive material will depend on the chemical composition and other properties of the additive material. In general, the amount of additive will 15 be not more than 50% by weight, based on the total weight of the formulations. However, it is thought that for most additives the amount of additive material should be not more than 10%, more advantageously not more than 5%, preferably not more than 4% and for most materials will be 20 not more than 2% or even not more than 1% by weight or not more than 0.25% based on the total weight of the formulation. In general, the amount of additive material is at least 0.01% by weight based on the total weight of the formulation.

25 Advantageously the additive material is an anti-adherent material and will tend to decrease the cohesion between the anti-adherent materials and the carrier particles. In order to determine whether a given material is an anti-adherent material, the test described in 30 International Specification WO97/03649 (pages 6 and 7)

using an "Aeroflow" apparatus may be used, anti-adherent materials being those additive materials that result in a lowering of the mean time between avalanches of the powder, as compared with the powder in the absence of the additive 5 material.

Advantageously the additive material is an anti-friction agent (glidant) and will give better flow of powder in the dry powder inhaler which will lead to a better dose reproducibility from the inhaler device.

10. Where reference is made to an anti-adherent material, or to an anti-friction agent, the reference is to include those materials which will tend to decrease the cohesion between the active particles and the carrier particles, or which will tend to improve the flow of powder in the 15 inhaler, even though they may not usually be referred to as anti-adherent material or an anti-friction agent. For example, leucine is an anti-adherent material as herein defined and is generally thought of as an anti-adherent material but lecithin is also an anti-adherent material as 20 herein defined, even though it is not generally thought of as being anti-adherent, because it will tend to decrease the cohesion between the active particles and the carrier particles. Advantageously, the additive material consists of physiologically acceptable material. As already 25 indicated, it is preferable for only small amounts of additive material to reach the lower lung, and it is also highly preferable for the additive material to be a material which may be safely inhaled into the lower lung where it may be absorbed into the blood stream. That is

especially important where the additive material is in the form of particles.

The additive material may include a combination of one or more materials.

5 It will be appreciated that the chemical composition of the additive material is of particular importance.

It will furthermore be appreciated that additive materials that are naturally occurring animal or plant substances will offer certain advantages.

10 Advantageously, the additive material includes one or more compounds selected from amino acids and derivatives thereof, and peptides and polypeptides having molecular weight from 0.25 to 100Kda, and derivatives thereof. Amino acids, peptides or polypeptides and their derivatives are 15 both physiologically acceptable and give acceptable release of the active particles on inhalation.

It is particularly advantageous for the additive material to comprise an amino acid. Amino acids have been found to give, when present in low amounts in a powder as 20 additive material, high respirable fraction of the active materials with little segregation of the powder and also with very little of the amino acid being transported into the lower lung. In respect of leucine, a preferred amino acid, it is found that, for example, for an average dose of 25 powder only about 10 μ g of leucine would reach the lower lung. The additive material may comprise one or more of any of the following amino acids: leucine, isoleucine, lysine, valine, methionine, phenylalanine. The additive may be a salt of a derivative of an amino acid, for example 30 aspartame or acesulfame K. Preferably, the additive

particles consist substantially of leucine, advantageously L-leucine. As indicated above, leucine has been found to give particularly efficient release of the active particles on inhalation. Whilst the L-form of an amino acid is used 5 in Examples described below, the D- and DL-forms may also be used.

Additive materials which comprise one or more water soluble substances offer certain advantages. This helps absorption of the substance by the body if the additive 10 reaches the lower lung. The additive material may include dipolar ions, which may consist of zwitterions.

Alternatively, the additive material may comprise particles of a phospholipid or a derivative thereof. Lecithin has been found to be a good material for the 15 additive material.

The additive material may include or consist of one or more surface active materials, in particular materials that are surface active in the solid state, which may be water soluble, for example lecithin, in particular soya lecithin, 20 or substantially water insoluble, for example solid state fatty acids such as lauric acid, palmitic acid, stearic acid, erucic acid, behenic acid, or derivatives (such as esters and salts) thereof. Specific examples of such materials are: magnesium stearate; sodium stearyl fumarate; sodium stearyl lactylate; phosphatidylcholines, 25 phosphatidylglycerols and other examples of natural and synthetic lung surfactants; liposomal formulations; lauric acid and its salts, for example, sodium lauryl sulphate, magnesium lauryl sulphate; triglycerides such as Dynsan 118 and Cutina HR; and sugar esters in general.

Other possible additive materials include talc, titanium dioxide, aluminium dioxide, silicon dioxide and starch.

The expression "additive material" as used herein does not include crystalline sugars. Whereas small particles of one or more crystalline sugars may be present, and are indeed preferred to be present, as described below, formulations which contain small crystalline sugar particles will also contain a further substance which is an additive material in the sense in which that expression is used herein.

In the case of certain additive materials, it is important for the additive material to be added in a small amount. For example, magnesium stearate is highly surface active and should therefore be added in small amounts, for example, up to 2.5%, by weight based on the weight of the formulation with amounts of from 0.1 to 2% being preferred, for example, 0.5% to 1.7% especially 0.75 to 1.5% by weight. In some cases, it might be found advantageous to use smaller amounts of magnesium stearate, for example, from 0.02 to 0.6%, or 0.2 to 0.4% by weight.

Phosphatidylcholines and phosphatidylglycerols on the other hand are less active and can usefully be added in greater amounts. In respect of leucine, which is still less active, an addition of 2% by weight leucine based on the weight of the powder gives good results in respect of the respirable fraction of the active particles, low segregation and low amount of leucine reaching the lower lung; it is explained in WO 96/23485 that an addition of a greater amount does not improve the results and in

particular does not significantly improve the respirable fraction and therefore whilst even with 6% leucine a reasonable result is obtained that is not preferred since it results in an increased quantity of additive material 5 being taken into the body and will adversely affect the processing properties of the mix. In the preferred formulations of the present invention using fissured carrier particles, however, it has been found that increased amounts of additive material may be used and give 10 improved respirable fractions.

The additive material will often be added in particulate form but it may be added in liquid or solid form and for some materials, especially where it may not be easy to form particles of the material and/or where those 15 particles should be especially small, it may be preferred to add the material in a liquid, for example as a suspension or a solution or as a melt. Even then, however, the additive material of the finished powder may be in particulate form. An alternative possibility, however, 20 that is within the scope of the invention is to use an additive material which remains liquid even in the final essentially particulate material which can still be described as a "dry powder".

In some cases improved clinical benefits will be 25 obtained where the additive material is not in the form of particles of material. In particular, the additive material is less likely to leave the surface of the carrier particle and be transported into the lower lung.

Where the additive material of the finished powder is 30 particulate, the nature of the particles may be

significant. The additive particles may be non-spherical in shape. Advantageously, the additive particles are plate-like particles. Alternatively, the additive particles may be angular for example prisms, or dendritic 5 in shape. Additive particles which are non-spherical may be easier to remove from the surfaces of the carrier particles than spherical, non-angular particles and plate-like particles may give improved surface interaction and glidant action between the carrier particles.

10 The surface area of the additive particles is also thought to be important. The surface area of the additive particles, as measured using gas absorption techniques, is preferably at least $5\text{m}^2\text{g}^{-1}$. In many cases it is found that additive material comprising small plate-like particles is 15 preferred.

Advantageously, at least 90% by weight of the additive particles have an aerodynamic diameter less than $150\mu\text{m}$, more advantageously less than $100\mu\text{m}$, preferably less than $50\mu\text{m}$. Advantageously, the MMAD of the additive particles 20 is not more than $20\mu\text{m}$, preferably not more than $15\mu\text{m}$, and more preferably not more than $10\mu\text{m}$. The additive particles preferably have a mass median diameter less than the mass median diameter of the carrier particles and will usually have a mass median diameter of approximately between a 25 tenth and a thousandth, for example, between a fiftieth and a five hundredth that of the carrier particles. The MMAD of the additive particles will generally be not less than $0.1\mu\text{m}$, for example, not less than $1\mu\text{m}$.

The amount of additive material will depend upon the 30 nature of the additive material, and will generally be at

least 0.01% based on the weight of the carrier particles. In the case of additive materials that do not tend to segregate from the carrier particles, the additive material may be present in amounts of up to 50%, by weight, based on 5 the weight of the carrier particles and additive. Advantageously, the additive material may constitute up to one third of the combined weight of additive and carrier particles. In general, the amount of additive material will not exceed 10%, and preferably not exceed 5%, of the 10 combined weight of additive and carrier particles.

In the use of those additive materials which do have a tendency to segregate, the amount of additive material will generally be less than 5%, for example not more than 3% by weight based on the combined weight of additive material 15 and carrier particles.

The active particles referred to throughout the specification will comprise an effective amount of at least one active agent that has therapeutic activity when delivered into the lung. The active particles 20 advantageously consist essentially of one or more therapeutically active agents. Suitable therapeutically active agents may be drugs for therapeutic and/or prophylactic use. Active agents which may be included in the formulation include those products which are usually 25 administered orally by inhalation for the treatment of disease such a respiratory disease, for example, β -agonists.

The active particles may comprise at least one β_2 -agonist, for example one or more compounds selected from 30 terbutaline, salbutamol, salmeterol and formoterol. If

desired, the active particles may comprise more than one of those active agents, provided that they are compatible with one another under conditions of storage and use.

Preferably, the active particles are particles of
5 salbutamol sulphate. References herein to any active agent are to be understood to include any physiologically acceptable derivative. In the case of the β_2 -agonists mentioned above, physiologically acceptable derivatives include especially salts, including sulphates.

10 The active particles may be particles of ipatropium bromide.

The active particles may include a steroid, which may be beclometasone dipropionate or may be fluticasone. The active principle may include a cromone which may be sodium
15 cromoglycate or nedocromil. The active principle may include a leukotriene receptor antagonist.

The active particles may include a carbohydrate, for example heparin.

The active particles may advantageously comprise a
20 therapeutically active agent for systemic use provided that that agent is capable of being absorbed into the circulatory system via the lungs. For example, the active particles may comprise peptides or polypeptides or proteins such as DNase, leukotrienes or insulin (including
25 substituted insulins and pro-insulins), cyclosporin, interleukins, cytokines, anti-cytokines and cytokine receptors, vaccines (including influenza, measles, 'anti-narcotic' antibodies, meningitis), growth hormone, leuprolide and related analogues, interferons,
30 desmopressin, immunoglobulins, erythropoietin, calcitonin

and parathyroid hormone. The formulation of the invention may in particular have application in the administration of insulin to diabetic patients, thus avoiding the normally invasive administration techniques used for that agent.

5 The formulations of the invention may advantageously be for use in pain relief. Non-opioid analgesic agents that may be included as pain relief agents are, for example, alprazolam, amitriptyline, aspirin, baclofen, benzodiazepines, bisphosphonates, caffeine, calcitonin,

10 calcium-regulating agents, carbamazepine, clonidine, corticosteroids, dantrolene, dexamethasone, disodium pamidronate, ergotamine, flecainide, hydroxyzine, hyoscine, ibuprofen, ketamine, lignocaine, lorazepam, methotriimeprazine, methylprednisolone, mexiletine,

15 mianserin, midazolam, NSAIDs, nimodipine, octreotide, paracetamol, phenothiazines, prednisolone, somatostatin. Suitable opioid analgesic agents are: alfentanil hydrochloride, alphaprodine hydrochloride, anileridine, bezitramide, buprenorphine hydrochloride, butorphanol tartrate, carfentanil citrate, ciramadol, codeine, dextromoramide, dextropropoxyphene, dezocine, diamorphine hydrochloride, dihydrocodeine, dipipanone hydrochloride, enadoline, eptazocine hydrobromide, ethoheptazine citrate, ethylmorphine hydrochloride, etorphine hydrochloride,

20 fentanyl citrate, hydrocodone, hydromorphone hydrochloride, ketobemidone, levomethadone hydrochloride, levomethadyl acetate, levorphanol tartrate, meptazinol hydrochloride, methadone hydrochloride, morphine, nalbuphine hydrochloride, nicomorphine hydrochloride, opium,

25 hydrochlorides of mixed opium alkaloids, papaveretum,

oxycodone, oxymorphone hydrochloride, pentamorphone, pentazocine, pethidine hydrochloride, phenazocine hydrobromide, phenoperidine hydrochloride, picenadol hydrochloride, piritramide, propiram furmarate, 5 remifentanil hydrochloride, spiradoline mesylate, sufentanil citrate, tilidate hydrochloride, tonazocine mesylate, tramadol hydrochloride, trefentanil.

The technique could also be used for the local administration of other agents for example for anti cancer 10 activity, anti-virals, antibiotics, muscle relaxants, antidepressants, antiepileptics or the local delivery of vaccines to the respiratory tract.

The active particles advantageously have a mass median aerodynamic diameter in the range of up to 15 μm , for 15 example from 0.01 to 15 μm , preferably from 0.1 to 10 μm , for example, from 1 to 8 μm . Most preferably, the mass median aerodynamic diameter of the active particles is not exceeding 5 μm . The active particles are present in an effective amount, for example, at least 0.01% by weight, 20 and may be present in an amount of up to 90% by weight based on the total weight of carrier particles, additive materials and active particles. Advantageously, the active particles are present in an amount not exceeding 60% by weight based on the total weight of carrier particles, 25 additive particles and active particles.

It will be appreciated that the proportion of active agent present will be chosen according to the nature of the active agent. In many cases, it will be preferred for the active agent to constitute no more than 10%, more 30 preferably no more than 5%, and especially no more than 2%

by weight based on the total weight of carrier particles, additive particles and active particles.

The formulation may further comprise fine particles of an excipient material, that is to say, particles of

5 aerodynamic diameter not more than 50 μm , of a substantially inert pharmacologically acceptable material. The excipient material may be any substantially inert material that is suitable for use as an excipient in an inhalable formulation. The excipient material preferably comprises

10 one or more crystalline sugars, for example, dextrose and/or lactose. Most preferably the excipient material consists essentially of lactose.

Advantageously, the fine excipient particles are of the same material as the carrier particles. It is

15 especially preferred for the carrier particles and the fine excipient particles to be of lactose.

Advantageously, at least 90% by weight of the fine excipient particles have an aerodynamic diameter of not more than 40 μm . The fine excipient particles

20 advantageously have an MMAD of not more than 20 μm , preferably not more than 15 μm , more preferably not more than 10 μm , and especially not more than 8 μm . The MMAD of the fine excipient particles will generally be not less than 0.1 μm , for example not less than 1 μm . Advantageously

25 the fine excipient particles are present in an amount of up to 50%, for example from 0.1 to 20%, and preferably from 1 to 15%, by weight based on the total weight of the formulation.

Where fine excipient particles are present, they may

30 be present in an amount of up to 99% by weight of the total

weight of fine excipient particles and additive material. Advantageously, fine excipient particles are present in an amount of at least 30%, preferably at least 50% and especially at least 90% by weight, based on the total

5 weight of fine excipient particles and additive material. The fine excipient particles and additive material, advantageously constitute from 5%, or from 10% to two thirds by weight of the total weight of fine excipient particles, additive material and carrier particles.

10 Where, as is preferred, the carrier particles and the fine excipient particles are of the same compound, for example, lactose, it may be found convenient to consider all the particles of that compound having an aerodynamic diameter of less than 50 μm to be fine excipient particles,

15 whilst particles of aerodynamic diameter of 50 μm or more are regarded as carrier particles.

The advantageous flow properties of formulations of the invention may be demonstrated, for example, using a Flodex Tester, which can determine a flowability index over

20 a scale of 4 to 40mm, corresponding to a minimum orifice diameter through which smooth flow of the formulation occurs in the Tester. The flowability index, when so measured, of formulations of the invention containing fissured lactose will generally be below 12mm, even where

25 fine particle contents (that is, particles of aerodynamic diameter less than 50 μm or preferably less than 20 μm) exceed 10% by weight of the formulation.

The invention provides a formulation for use in a dry powder inhaler, comprising more than 5%, preferably more

30 than 10% by weight, based on the total weight of the formulation, of particles of aerodynamic diameter less than

20 μ m, the formulation having a flowability index of 12mm or less. The term "flowability index" as used herein refers to flowability index values as measured using a Flodex Tester.

5 In addition to the carrier particles, active particles and fine excipient particles, the formulation may comprise one or more further additives suitable for use in inhaler formulations, for example, flavourings, lubricants, and flow improvers. Where such further additives are present, 10 they will generally not exceed 10% by weight of the total weight of the formulation.

The formulations of the invention may be made by combining the components in any suitable manner. In a preferred method, however, the formulations are made by 15 mixing the additive and fine excipient particles in a high energy mixing step, mixing the composite particles so obtained with the carrier particles, and adding to the mixture so obtained the at least one active ingredient. In another advantageous method, additive particles and 20 excipient particles are co-micronised so as to significantly reduce their particle size, the co-micronised particles are mixed with the carrier particles, and the at least one active ingredient is added to the mixture so obtained. Suitable mixers for carrying out a high energy 25 mixing step in the context of such formulations are high shear mixers. Such mixers are known to those skilled in the art, and include, for example, the Cyclomix and the Mechano-Fusion mixers manufactured by Hosokawa Micron. It will be appreciated by those skilled in the art that other 30 suitable apparatus for use in a high energy mixing step

will include, for example, ball mills and jet mills, provided that the equipment and conditions are so arranged to effect the desired high energy mixing.

5 The formulation may be a powder formulation for use in a dry powder inhaler. The formulation may be suitable for use in a pressurised metered dose inhaler.

One embodiment of the invention will now be described in detail with reference to the accompanying illustrations in which:

10 Fig. 1 is a scanning electron micrograph (SEM) of a relatively highly fissured lactose particle;

Fig. 2 is an SEM at lower magnification than Fig. 1 showing a number of lactose particles;

15 Fig. 3 is an SEM of a lactose carrier particle loaded with leucine and salbutamol sulphate; and

Fig. 4 is an SEM of a formulation containing conventional lactose carrier particles and fine excipient particles.

20 With reference to Fig. 1, it may be seen that the lactose carrier particle consists of a number of individual lactose crystals which are fused to one another. The crystals define between them at the surface of the particle a multiplicity of relatively deep fissures or crevices.

25 Such particles are known and have previously been regarded as suitable for use in tablet manufacture. Surprisingly, it has been found that carrier particles such as that shown in Fig. 1 are able to enhance the fine particle fraction of an active substance in the presence of additive. The active substance, together with the fine excipient, tend 30 because of their small particle size and consequent high

surface energy to adhere to the carrier particles. Adhesion occurs predominantly within the fissures and crevices. Due to the optimum width, depth and shape of the fissures, the resultant loaded carrier particles have good 5 stability against deagglomeration within the inhaler device and yet permit effective dispersion of the active particles and fine excipient on expulsion from the device after actuation.

Fig. 2 shows a group of carrier particles similar to 10 that of Fig. 1.

Referring to Figs. 3 and 4, the lactose carrier particle of Fig. 3 holds the fine material, consisting of leucine as additive material and salbutamol sulphate as active material, within the fissures of its agglomerated 15 structure to form a relatively cohesive structure, whilst in the conventional formulation of Fig. 4 much of the fine material is not adhered to the lactose carrier particles. The conventional carrier particles are typically crystals which have the characteristic tomahawk shape of lactose 20 crystals. They may also be amorphous in shape, but rarely consist of more than two fused crystals. Thus the conventional carrier particles are substantially without the clefts and valleys of the fissured particles used in accordance with the present invention.

25 References herein to a "diameter" in relation to carrier particles means the diameter determined using laser diffraction, for example, using a Malvern Mastersizer, and references herein to a "mass median diameter" in relation to carrier particles is to be interpreted accordingly.

It may be found convenient to determine the diameters of particles in a formulation according to the invention by dispersing the particles in a liquid that does not dissolve any of the component particles, sonicating to ensure

5 complete dispersion, and analysing the dispersion by means of laser diffraction, for example using a Malvern Mastersizer. That method will be suitable where separate analysis of fine particles of different materials is unnecessary.

10 In practice, it may be desired to examine a larger particle size fraction separately from a smaller size fraction. In that case, an air jet sieve may be used to effect separation. A mesh corresponding to the desired diameter at which the separation is to be effected is then

15 used in the air jet sieve. A mesh corresponding to a diameter of 50 μ m may thus be used for separation, larger particles being retained by the sieve whilst smaller particles pass through to be collected on a filter. That enables different techniques to be applied to analysis of

20 the larger particles ($\geq 50\mu$ m) and the smaller particles ($< 50\mu$ m) if desired.

In the case of particles of the size of the carrier particles used in accordance with the invention, the diameter as measured using laser diffraction approximates

25 the aerodynamic diameter. If preferred, therefore, the aerodynamic diameters of the carrier particles may be determined and the mass median aerodynamic diameter (MMAD) calculated therefrom.

MMADs referred to herein in relation to additive

30 materials, fine excipient particles and active particles

may be measured using any suitable technique, for example, using an impactor such as a cascade impactor, and analysing the size fractions so obtained, for example using HPLC.

Alternatively, respective samples of the formulation 5 may each be treated with a solvent that is known to dissolve one or more, but not all, of the ingredients and examining the undisolved particles by any suitable method, for example, laser diffraction.

The following Examples illustrate the invention.

10 Example 1

20g of Microfine lactose (Burculo - MMAD about 8 μ m) and 0.4g of L-leucine (Ajinomoto) were combined and placed in a stainless steel ball mill, filled with stainless steel balls of varying diameter to approximately 50% of the mill 15 volume. The mill was rotated at approximately 60RPM for about 120 minutes. The milled material (MMAD about 5 μ m) was then recovered from the mill and from the surface of the balls, and is referred to below as the fines.

8g of sieved Prismalac lactose was weighed into a 20 glass vessel. Prismalac (trade mark) lactose is sold in the UK by Meggle for use in tablet manufacture. The lactose, as purchased, had been sieved on a stack of sieves in order to recover the sieve fraction passing through a 600 μ m mesh sieve, but not passing through a 355 μ m mesh 25 sieve. That fraction is referred to below as 355-600 Prismalac and has a mean tapped density of 0.49g/cm³ and a bulk density as measured by mercury intrusion porosimetry of 0.47g/cm³.

1g of the fines obtained as described above, and 1g of 30 micronised salbutamol sulphate (MMAD~2 μ m) was added to the

355-600 Prismalac in the glass vessel. The glass vessel was sealed and the vessel located in a "Turbula" tumbling blender. The vessel and contents were tumbled for approximately 30 minutes at a speed of 42RPM.

5 The formulation so obtained was loaded into size 3 gelatin capsules at 20mg per capsule. The loaded capsules were rested for a period of 24 hours. Three capsules were then fired sequentially into a Twin Stage Impinger from a Cyclohaler at a flow rate of 60 litres per minutes, with a 10 modified stage 1 jet of 12.5mm internal diameter, which was estimated to produce a cut-off diameter of 5.4 μ m. The operation of the Twin Stage Impinger is described in WO95/11666. Modification of a conventional Twin Stage Impinger, including the use of modified stage 1 jets, is 15 described by Halworth and Westmoreland (J. Pharm. Pharmacol. 1987, 39:966-972).

Table 1

	Example 1		Comparison 1	Comparison 2
355-600 Prismalac lactose	8g	80%	8g	4g
Salbutamol sulphate	1g	10%	1g	0.5g
Microfine lactose	0.9804g	9.804%	-	0.5g
Leucine	0.0196g	0.196%		-
Fine particle fraction	50%		10%	40%

20 The composition of the formulation is summarised in Table 1 above.

As shown in Table 1, the fine particle fraction is improved in the presence of added fine lactose (Comparison 2) as compared with a formulation which contains no added

fine lactose (Comparison 1). The best performance is obtained from the formulation according to the invention, containing leucine as well as fine lactose. On omission of the Prismalac from the ingredients of Example 1, the 5 formulation was found to have very poor flow properties, preventing reliable and reproducible metering. As a result, the fine particle fraction was found to be very variable.

Example 2

10 Example 1 was repeated using micronised budesonide (MMAD 2 μ m) in place of salbutamol sulphate, and magnesium stearate in place of leucine. The results are summarised in Table 2, which also indicates the amounts of each ingredient.

15 Table 2

355-600 Prismalac lactose	4g	80%
Budesonide	0.5g	10%
Microfine lactose	0.45g	9%
Magnesium stearate	0.05g	1%
Fine particle fraction	40%	

Example 3

Example 1 was repeated using Prismalac lactose which had been sieved, the sieve fractions of 212 to 355 μ m (with 20 mean tapped density 0.65g/cm³ and a bulk density as measured by mercury instrusion porosimetry of 0.57g/cm³) being recovered and used instead of the 355-600 Prismalac

lactose used in Example 1. Once again, a fine particle fraction of about 50% was obtained.

Example 4

Example 1 was repeated replacing the leucine by one of 5 the following: lecithin, stearylamine, magnesium stearate, and sodium stearyl fumarate.

The results are summarised in Table 3.

Table 3

Additive	Fine particle fraction
Lecithin	50%
Stearylamine	50%
Purified phosphatidyl cholines	35%
Sodium stearyl fumarate	40%

10 Example 5

Micronised salbutamol sulphate was mixed with 5% by weight of sublimed L-leucine in a blender. The mixture so obtained was then tumbled in the ratio of 1:6 with Prismalac (355 to 600 μ m fraction) for 15 minutes. The fine 15 particle fraction, determined using a Twin Stage Impinger modified as described in Example 1, was 65%.

Example 6

95g of Microfine lactose (Borcuso) was placed in a ceramic milling vessel (manufactured by the Pascall 20 Engineering Company). 5g of additive material (L-leucine) and the ceramic milling balls were added. The ball mill was tumbled at 60rpm for 5 hours. The powder was recovered by sieving to remove the milling balls.

0.9g of the composite excipient particles so obtained 25 containing 5% L-leucine in Microfine lactose was blended

with 0.6g of budesonide by hand in a mortar. This blending could also be performed, for example, in a high shear blender, or in a ball mill or in a centrifugal mill. 20 parts by weight of this powder were blended with 80 parts 5 by weight of a coarse carrier lactose (sieve-fractionated Prismalac - 355 to 600 μ m fraction) by tumbling. The powder was fired from a Cyclohaler at a flow rate of 60l/minute in a multi-stage liquid impinger. The fine particle fraction (< approx. 5 μ m) was 45%.

10 Example 7

98g of Microfine (MMAD approximately 8 μ m) lactose (manufactured by Borculo) was placed in a stainless steel milling vessel. 300g of stainless steel milling balls varying from 10 to 3mm diameter were added. 2g of lecithin 15 was added and the vessel was located in a Retsch S100 Centrifugal Mill. The powder was milled for 30 minutes at 580rpm and was then sieved to remove the milling balls.

1g of salbutamol sulphate was added to 1g of the composite excipient particles so obtained containing 2% 20 lecithin, and to 8g of sieve-fractionated Prismalac lactose (355 to 600 μ m fraction). The mixture was tumbled for 30 minutes at 42rpm. The resulting powder was fired from a Cyclohaler at a flow rate of 60 litres per minute into a twin-stage impinger, giving a fine particle fraction (< approx. 5 μ m) of about 44%. A similar example with a 2% 25 leucine precursor gave a fine particle fraction (< approx. 5 μ m) of 52%.

Other additive materials that may be used instead of lecithin to form composite excipient particles as described 30 above are: magnesium stearate, calcium stearate, sodium

stearate, lithium stearate, stearic acid, stearylamine, soya lecithin, sodium stearyl fumarate, l-leucine, l-isoleucine, oleic acid, starch, diphosphatidyl choline, behenic acid, glyceryl behenate, and sodium benzoate.

5 Pharmaceutically acceptable fatty acids and derivatives, waxes and oils may also be used.

Example 8

10g of Microfine lactose (Borculo) was combined with 1g of magnesium stearate and 10cm³ cyclohexane. 50g of 5mm 10 balls were added and the mixture was milled for 90 minutes. The powder was recovered by leaving the paste in a fume hood overnight to evaporate the cyclohexane and then ball milling for 1 minute.

15 0.5g of salbutamol sulphate was added to 0.5g of the composite excipient particles so obtained containing magnesium stearate, and to 4g of sieve-fractionated Prismalac lactose (355-600μm fraction). This was tumbled for 30 minutes at 62rpm. The resulting powder was fired from a Cyclohaler at a flow rate of 60 litres per minute 20 into a twin-stage impinger, giving a fine particle fraction (< approx. 5μm) of 57%. The experiment was repeated using composite excipient particles containing 20% magnesium stearate and similar results were obtained.

Example 9

25 10g of Microfine lactose (Borculo) was combined with 1g of leucine and 10cm³ cyclohexane. 50g of 5mm balls were added and the mixture was milled for 90 minutes. The powder was recovered by leaving the paste in a fume hood overnight to evaporate the cyclohexane and then ball 30 milling for 1 minute.

0.5g of salbutamol sulphate, 0.25g of composite excipient particles made as described in Example 8 containing magnesium stearate, 0.25g of composite excipient particles made as described above containing leucine, and 5 4g of sieve-fractionated Prismalac (355-600 μ m fraction) were all combined. The mixture was tumbled for 30 minutes at 62rpm. The resulting powder was fired from a Cyclohaler at a flow rate of 60 litres per minute into a twin-stage impinger, giving a fine particle fraction (< approx. 5 μ m) 10 of ~65%.

Example 10

10g of Microfine lactose (Borcuso) was combined with 1g of lecithin and 10cm³ cyclohexane. 50g of 5mm balls were added and the mixture was milled for 90 minutes. The 15 powder was recovered by leaving the paste in a fume hood overnight to evaporate the cyclohexane and then ball milling for 1 minute.

0.5g of salbutamol sulphate was added to 0.25g of the composite excipient particles so obtained containing 20 lecithin, 0.25g of composite excipient particles made as described in Example 9 containing leucine, and 4g of sieve-fractionated Prismalac lactose (355-600 μ m fraction). The mixture was tumbled for 30 minutes at 62rpm. The resulting powder was fired from a Cyclohaler at a flow rate of 60 25 litres per minute into a twin-stage impinger, giving a fine particle fraction (< approx. 5 μ m) of 68%.

Example 11

95g Sorbolac 400 (Meggle) were combined with 5g of magnesium stearate and 50ml dichloromethane and milled in a 30 Retsch S100 centrifugal mill with 620g of 5mm stainless

steel balls in a stainless steel vessel for 90 minutes at 500rpm. The powder was recovered after evaporation of the dichloromethane by briefly milling (1 minute) and subsequent sieving. 10g of the composite excipient/

5 additive particles so obtained were added to 89.5g of sieve fractionated Prismalac lactose (355-600 μ m fraction). The mixture was tumbled for 30 minutes at 60rpm, then 0.5g budesonide was added and tumbling continued for a further 30 minutes at 60rpm. The powder was fired from a

10 Cyclohaler at 60l/minute into a Twin-Stage Impinger, and gave a fine particle fraction (< approx. 5 μ m) of about 80%.

Example 12

(a) A pre-blend was made by milling an additive material and microfine lactose (<20 micron) together in a ball mill.

15 Then 1g of the pre-blend, 1g of salbutamol sulphate and 8g of coarse lactose (Prismalac 355-600 μ m fraction) were mixed together in a glass vessel in a Turbula mixer at 42rpm to create the final formulation. Size 2 capsules were filled with 20mg of the formulation. For each test, 3 capsules

20 were fired into a 'rapid TSI' from a cyclohaler giving a total delivered dose of 6mg of salbutamol sulphate per test. The additive material was selected from lithium stearate, calcium stearate, magnesium stearate, sodium stearate, sodium stearyl fumarate, leucine, lecithin and

25 stearylamine.

(b) The method of (a) above was repeated using leucine, except that the pre-blend was mixed with the coarse lactose in a glass vessel shaken by hand.

The "rapid TSI" is a modified methodology based on a

30 conventional TSI. In the rapid TSI the second stage of the

impinger is replaced by a glass fibre filter (Gelman A/E, 76mm). This enables the fine particle fraction of the formulation (i.e. particles with an MMAD<5 μ m) to be collected on a filter for analysis. Analysis was conducted 5 by sonicating the filter in a 0.06M NaOH solution and analysed at 295nm on a UV spectrophotometer (Spectronic 601). The fine particle fraction corresponds substantially to the respirable fraction of the formulation.

Further details of the formulations and the % fine 10 particle fraction estimated using the "rapid TSI" method described above are given in Table 4 below.

Segregation has not been observed in the above formulations, even those comprising 10 and 20% magnesium stearate (i.e. up to 2% in the final composition).

15 The above processes have been applied to a variety of active materials. When the active material is a protein, the milling may be preceded by lyophilisation (freeze drying) of the protein either pure or in combination with an additive material and/or a polymeric stabiliser. The 20 freeze drying may make the protein more brittle and more easily milled. The milling may need to be conducted under cryogenic (cold) conditions to increase the brittleness of the material.

Table 4

Additive Material ("AM")	% AM in pre-blend	% AM in formulation	Mass (mg) SaSO ₄	Estimated % FPF	Pre-blend mill method
Lithium St	2	0.2	2.549	42	30 mins
			2.763	46	
Calcium St	2	0.2	2.721	45	1 hr
			2.633	44	
Magnesium St	2	0.2	2.108	35	1 hr
			2.336	39	
Sodium St	2	0.2	3.218	54	30 mins
			3.153	53	
Sodium stearyl Fumarate	2	0.2	2.261	38	30 mins
			2.113	35	
Leucine	2	0.2	2.429	40	2 hrs
			2.066	34	
Leucine [12(b)]	2	0.2	2.136	36	2 hrs
			2.600	43	
Leucine	5	0.5	2.782	46	30 mins
			3.000	50	
Leucine	5	0.5	2.772	46	5 hrs
			2.921	49	
Magnesium St	5	0.5	2.438	41	30 mins
			2.721	45	
Lecithin	2	0.2	3.014	50	30 mins
			2.884	48	
Stearylamine	2	0.2	2.847	47	30 mins
			3.037	51	

Example 13

Determination of the suitable amount of magnesium stearate to be added in the formulation.

Samples of pre-blends were prepared by co-milling in a ball milling apparatus for 2 hours α -lactose monohydrate SorboLac 400 (Meggle microtose) with a starting particle size below 30μ ($d(v, 0.5)$ of about $10\mu\text{m}$) and magnesium stearate with a starting particle size of 3 to $35\mu\text{m}$ ($d(v, 0.5)$ of about $10\mu\text{m}$) in the ratio 98:2, 95:5 and 90:10% by weight (blends A).

85% by weight of α -lactose monohydrate CapsuLac (212-355 μm) was placed in a 240ml stainless steel container, 15 then 15% by weight of a respective blend A was added. The

blend was mixed in a Turbula mixer for 2 hours at 42rpm (blend B). Micronised formoterol fumarate was added to the blend B and mixed in a Turbula mixer for 10 mins at 42rpm to obtain a ratio of 12 μ g of active to 20mg of carrier.

5 The final formulation (hard pellet formulation) was left to stand for 10 mins then transferred to an amber glass jar.

The amount of magnesium stearate in the final formulations turns out to be 0.3, 0.75 and 1.5% by weight, respectively. The uniformity of distribution of active 10 ingredient and the in-vitro aerosol performance were determined as follows:

a) The uniformity of distribution of the active ingredient was evaluated by withdrawing 10 samples, each equivalent to about a single dose, from different parts of the blend. The 15 amount of active ingredient of each sample was determined by High-Performance Liquid Chromatography (HPLC).
b) Determination of the aerosol performances.

An amount of powder for inhalation was loaded in a multidose dry powder inhaler (Pulvinal® - Chiesi 20 Pharmaceutical SpA, Italy).

The evaluation of the aerosol performances was performed by using a modified Twin Stage Impinger apparatus, TSI (Apparatus of type A for the aerodynamic evaluation of fine particles described in FU IX, 4° supplement 1996). The equipment consists of two different glass elements, mutually connected to form two chambers capable of separating the powder for inhalation depending on its aerodynamic size; the chambers are referred to as higher (stage 1) and lower (stage 2) separation chambers, 30 respectively. A rubber adaptor secures the connection

with the inhaler containing the powder. The apparatus is connected to a vacuum pump which produces an air flow through the separation chambers and the connected inhaler. Upon actuation of the pump, the air flow carries the particles of the powder mixture, causing them to deposit in the two chambers depending on their aerodynamic diameter. The apparatus used were modified in the Stage 1 Jet in order to obtained an aerodynamic diameter limit value, dae, of 5 μm at an air flow of 30 l/min, that is considered the relevant flow rate for Pulvinal[®] device. Particles with higher dae deposit in Stage 1 and particles with lower dae in Stage 2. In both stages, a minimum volume of solvent is used (30ml in Stage 2 and 7ml in Stage 1) to prevent particles from adhering to the walls of the apparatus and to promote the recovery thereof.

The determination of the aerosol performances of the mixture obtained according to the preparation process a) was carried out with the TSI applying an air flow rate of 30 l/min for 8 seconds.

After nebulization of 10 doses, the Twin Stage Impinger was disassembled and the amounts of drug deposited in the two separation chambers were recovered by washing with a solvent mixture, then diluted to a volume of 100 and 50 ml in two volumetric flasks, one for Stage 1 and one for Stage 2, respectively. The amounts of active ingredient collected in the two volumetric flasks were then determined by High-Performance Liquid Chromatography (HPLC). The following parameters, were calculated: i) the shot weight expressed as mean and relative standard

deviation (RSD) ii) the fine particle dose (FPD) which is the amount of drug found in stage 2 of TSI; iii) the emitted dose which is the amount of drug delivered from the device recovered in stage 1 + stage 2; iv) the fine particle fraction (FPF) which is the percentage of the emitted dose reaching the stage 2 of TSI.

Table 5 - Uniformity of distribution and *in-vitro* aerosol performances

	Mg stearate 0.3%	Mg stearate 0.75%	Mg stearate 1.5%
Content uniformity			
- Mean (µg)	11.84	-	-
- RSD (%)	1.83	-	-
Shot weight			
- Mean (mg)	20.8 4.28 49.9	24.7	23.0
- RSD (%)	6.9	6.5	2.4
Emitted dose (µg)	8.57	10.1	11.1
FPD (µg)	4.28	3.5	3.6
FPF (%)	49.9	35	32

10

In all cases, good performances in terms of fine particle dose are obtained, in particular with 0.3% by weight of magnesium stearate in the final formulation.

15 Example 14 - Effect of the addition of magnesium stearate by simple mixing

Formulation A - α -Lactose monohydrate Pharmatose 325M (30 -100µm) and magnesium stearate in the ratio 99.75:0.25% by weight were blended in a Turbula mixer for 2 hours at 42rpm. The blend was mixed with formoterol fumarate in a

Turbula mixer for 30 mins at 42rpm to obtain a ratio of 12 μ g of active to 25mg of carrier.

Formulation B - as reported above but α -Lactose monohydrate SpheroLac 100 (90-150 μ m) was used instead of 5 Pharmatose 325M.

Formulation C - α -Lactose monohydrate PrismaLac 40 (with a particle size below 355 μ m) and micronised lactose with a particle size below 5 μ m in the ratio 40:60% by weight were mixed in a Turbula mixer for 60 mins at 42rpm 99.75% 10 by weight of the resulting blend and 0.25% by weight of magnesium stearate were mixed in a Turbula mixer for 60 mins at 42rpm. The resulting blend was finally mixed with formoterol fumarate in a Turbula mixer for 30 mins at 42rpm to obtain a ratio of 12 μ g of active to 15mg of 15 carrier.

Formulation D - Sorbolac 400 with a particle size below 30 μ m ($d(v, 0.5)$ of about 10 μ m) and magnesium stearate in the ratio 98:2% by weight were mixed in a high shear mixer for 120 mins (blend A). 85% by weight α -lactose 20 monohydrate CapsuLac (212 - 355 μ m) and 15% by weight of blend A were mixed in Turbula for 2 hours at 42rpm (blend B); the amount of magnesium stearate in the final 25 formulation is 0.3% by weight. Micronised formoterol fumarate was placed on the top of blend B and mixed in a Turbula mixer for 10 mins at 42rpm to obtain a ratio of 12 μ g of active to 20mg of carrier.

Formulation E - Micronized lactose with a particle size below 10 μ m ($d(v, 0.5)$ of about 3 μ m) and magnesium stearate in the ratio 98:2% by weight were mixed in a 30 Sigma Blade mixer for 60 mins (blend A). 85% by weight

of α -lactose monohydrate CapsuLac (212 - 355 μ m) and 15% by weight of blend A were mixed in Turbula for 2 hours at 42rpm (blend B); the amount of magnesium stearate in the final formulation is 0.3% by weight. Micronised 5 formoterol fumarate was placed on the top of blend B and mixed in a Turbula mixer for 10 mins at 42rpm to obtain a ratio of 12 μ g of active to 20mg of carrier.

10 The results in terms of uniformity of distribution of active ingredient and in-vitro aerosol performances were determined as described in Example 13 and are reported in Table 6.

Table 6 - Uniformity of distribution of active ingredient and in-vitro aerosol performances

	Formulations A	Formulations B	Formulations C	Formulations D	Formulations E
Content uniformity					
- Mean (μ g)	7.96	10.50	9.10	10.68	11.32
- RSD (%)	2.16	8.30	24.90	2.80	3.0
Shot weight					
- Mean (mg)	24.10	26.50	12.50	22.07	21.87
- RSD (%)	34.60	8.20	15.30	2.50	4.0
Emitted dose (μ g)	6.10	7.60	9.60	8.60	9.93
FPD (μ g)	0.60	0.90	1.60	3.38	4.80
FPF (%)	9.8	11.8	16.7	39.3	48.37

15 Formulations where magnesium stearate is added by a high energy mixing to a small amount of fine lactose (blend A of the formulations D and E), and combined with a 212-355 μ m coarse lactose fraction, show a significant increase in performance. In addition, the particle size 20 of the fine lactose used has a significant effect on the deaggregation properties of the final formulation; in

fact, formulation E prepared using a micronized lactose shows a significant improved performance compared with formulation D.

5 Example 15 - Effect of the amount of micronized pre-blend in the final formulation

α -Lactose monohydrate SpheroLac 100 (Meggle EP D30) with a starting particle size of 50 to 400 μm ($d(v, 0.5)$) of about 170 μm and magnesium stearate with a starting particle size of 3 to 35 μm ($d(v, 0.5)$) of about 10 μm in 10 the ratio 98:2% by weight were co-milled in a jet mill apparatus (blend A) Different ratios of α -lactose monohydrate Capsulac (212-355 μm) and blend A were placed in a stainless steel container and mixed in a Turbula mixer for four hours at 32rpm (blends B).

15 Micronised formoterol fumarate was placed on the top of blends B and mixed in a Turbula mixer for 30 mins at 32rpm to obtain a ratio of 12 μg of active to 20mg total mixture. The amount of magnesium stearate in the final formulation ranges between 0.05 and 0.6% by weight.

20 The results in terms of uniformity of distribution of active ingredient and in-vitro aerosol performances were determined as in Example 13 and are reported in Table 7.

Table 7 - Uniformity of distribution of active ingredient and in-vivo aerosol performance

	Ratio 97.5:2.5	Ratio 95:5	Ratio 92.5:7.5	Ratio 90:10	Ratio 80:20	Ratio 70:30
Content uniformity						
- Mean (g)	11.29	12.25	11.53	11.93	11.96	12.00
- RSD (%)	3.8	5.7	1.5	2.5	2.0	2.0
Shot weight						
- Mean (mg)	19.27	20.26	20.38	21.05	22.39	22.48
- RSD (%)	4.7	3.3	3.2	4.3	3.5	3.7
Emitted dose (µg)	10.58	9.20	10.65	9.18	9.63	9.88
FPD (µg)	4.18	5.10	6.78	5.9	5.33	5.28
FPP (%)	39.4	55.4	63.6	64.3	55.3	53.4

5 The results indicate that the performances of all the formulations are good.

Example 16

10g of the composite excipient particles containing 5% magnesium stearate obtained in accordance with Example 11 were mixed with 89.5g coarse lactose (Prismalac; 355-600µm fraction) in a Turbula mixer for 30 minutes. 0.5g micronised dihydroergotamine mesylate was added and mixing continued in the Turbula for a further 30 minutes. The powder was fired from a Cyclohaler into a Multi-Stage Liquid Impinger (Apparatus C, European Pharmacopoeia, 15 Method 5.2.9.18, Supplement 2000), and gave a fine particle fraction (< approx. 5µm) of about 60%.

Example 17

Composite excipient particles were manufactured by milling 95g fine lactose (Sorbolac 400 - Meggle) with 5g magnesium stearate and 50ml dichloromethane in a Retsch S100 centrifugal mill with 620g of 5mm stainless steel balls in a stainless steel vessel for 90 minutes at 500rpm. The powder was recovered after evaporation of the dichloromethane by briefly milling (1 minute) and subsequent sieving. 10g of the composite excipient/additive particles so obtained were added to 89.5g of sieve fractionated Prismalac lactose (355-600 μ m fraction). The mixture was tumbled in a Turbula mixer for 30 minutes at 60rpm, then 0.5g fentanyl citrate was added and tumbling continued for a further 30 minutes at 60rpm. The powder so obtained was fired from a Cyclohaler at 60l/min into a Twin-Stage Impinger, and gave a fine particle fraction (< approx. 5 μ m) of about 50%.

Example 18

Various formulations, each combining 89.5g, 10g composite excipient particles and 0.5g budesonide were made according to the method of Example 11.

Their flowabilities were then measured using a FLODEX (trade mark) tester, made by Hanson Research. The FLODEX provides an index, over a scale of 4 to 40mm, of flowability of powders. Analysis was conducted by placing 50g of formulation into the holding chamber of the FLODEX via a funnel, allowing the formulation to stand for 1 minute, and then releasing the trap door of the FLODEX to open an orifice at the base of the holding chamber. Orifice diameters of 4 to 34mm were used to measure the

index of flowability. The flowability of a given formulation is determined as the smallest orifice diameter through which flowing of the formulation is smooth.

The results are shown in Table 8.

5 Comparison data is given for a formulation made by mixing for 30 minutes in a Turbula mixer 45g Pharmatose 325M lactose (a lactose used in certain conventional formulations) and 5g microfine lactose.

Table 8

Carrier particles	Composite particles	Flowability
Prismalac 355-600	Leucine:Sorbolac400 1:9	<4mm
Prismalac 355-600	Lecithin:Sorbolac400 1:9	<4mm
Prismalac 355-600	Magnesium stearate:Sorbolac400 1:19	<4mm
Prismalac 355-600	Magnesium stearate:microfine lactose 1:19	<4mm
Pharmatose 325M	Microfine lactose	<34mm

10

The results in Table 8 illustrate the excellent flowability of the fomulations according to the invention.

Comparison Example 1

15 99.5g of sieve-fractionated Prismalac (355-600 μ m fraction) was tumbled with 0.5g budesonide for 30 minutes at 60rpm. The powder, fired from a Cyclohaler at 90 litres per minute into a Multi-Stage Liquid Impinger gave a fine particle fraction (< approx. 5 μ m) of about 30%.

Claims

1. A formulation for use in an inhaler device, comprising carrier particles having a diameter of at least 50 μm and a mass median diameter of at least 175 μm ;
5 active particles; and additive material which is able to promote release of the active particles from the carrier particles on actuation of the inhaler device.
2. A formulation according to claim 1, in which the mass
10 median diameter of the carrier particles is at least 200 μm .
3. A formulation according to claim 1 or claim 2, in which the carrier particles are of a crystalline sugar.
4. A formulation according to claim 3, in which the carrier particles are of dextrose or lactose.
- 15 5. A formulation according to claim 4, in which the carrier particles are of lactose.
6. A formulation according to any one of claims 1 to 5, in which the carrier particles are of a material having a fissured surface.
- 20 7. A formulation according to any one of claims 1 to 6, in which the carrier particles are of a crystalline sugar having a tapped density not exceeding 0.75g/cm³.
8. A formulation according to claim 7, in which the carrier particles have a tapped density not exceeding
25 0.70g/cm³.
9. A formulation according to any one of claims 1 to 8, in which the carrier particles have a bulk density as measured by mercury intrusion porosimetry of not exceeding 0.6g/cm³.
- 30 10. A formulation according to any one of claims 1 to 9, in which the carrier particles are in the form of an

agglomerate consisting of a plurality of crystals fused to one another.

11. A formulation according to any one of claims 1 to 10, in which the carrier particles are obtainable by a wet 5 granulation process.

12. A formulation according to any one of claims 1 to 10, in which the carrier particles are dendritic spherulites.

13. A formulation according to any one of claims 1 to 12, in which the additive material is present in an amount of 10 not more than 50% by weight based on the weight of the formulation.

14. A formulation according to claim 13, in which the additive material is present in an amount of not more than 10% by weight based on the weight of the formulation.

15. 15. A formulation according to claim 14, in which the additive material is present in an amount of not more than 5% by weight based on the weight of the formulation.

16. A formulation according to any preceding claim, in which the additive material includes one or more compounds 20 selected from amino acids and derivatives thereof, and peptides and polypeptides having a molecular weight from 0.25 to 1000Kda, and derivatives thereof.

17. A formulation according to claim 16, in which the additive material comprises an amino acid.

25 18. A formulation according to claim 17, in which the additive material consists essentially of leucine.

19. A formulation according to any one of claims 1 to 17, in which the additive material comprises a phospholipid or a derivative thereof.

20. A formulation according to claim 19, in which the additive material comprises soya lecithin.
21. A formulation according to any one of claims 1 to 15, in which the additive material comprises one or more 5 compounds selected from the group consisting of magnesium stearate, calcium stearate, sodium stearate, lithium stearate, stearic acid, stearylamine, sodium stearyl fumarate, oleic acid, starch, behenic acid, glyceryl behenate and sodium benzoate.
- 10 22. A formulation according to claim 21, in which the additive is magnesium stearate.
23. A formulation according to any one of claims 1 to 15, in which the additive material is selected from fatty acids and derivatives, waxes and oils.
- 15 24. A formulation according to any one of claims 1 to 23, in which the additive material is in particulate form.
25. A formulation according to claim 24, in which at least 90% by weight of the additive particles have an aerodynamic diameter of less than 100µm.
- 20 26. A formulation according to claim 24 or claim 25, in which the mass median aerodynamic diameter of the additive particles is not more than about 10µm.
27. A formulation according to any preceding claim, which comprises not less than 0.01% by weight of additive material based on the weight of the formulation
- 25 28. A formulation according to any preceding claim, in which the additive material forms a discontinuous covering on the surfaces of the carrier particles.
29. A formulation according to claim 28, in which the 30 additive material, whilst forming a discontinuous covering

on the surfaces of the carrier particles, saturates the surfaces of the carrier particles.

30. A formulation according to any one of claims 1 to 29, which contains up to 90% by weight of active particles, 5 based on the total weight of active particles, additive material and carrier particles.

31. A formulation according to claim 30, which contains up to 50% by weight of active particles, based on the total weight of active particles, additive material and carrier 10 particles.

32. A formulation according to claim 31, which contains up to 20% by weight of active particles, based on the total weight of active particles, additive material and carrier particles.

15 33. A formulation according to any one of claims 1 to 32, which comprises at least 50% by weight carrier particles, based on the total weight of the formulation.

34. A formulation according to claim 33, which comprises at least 70% by weight carrier particles, based on the 20 total weight of the formulation.

35. A formulation according to any one of claims 1 to 34, in which the active particles comprise a therapeutically active agent for the prevention or treatment of respiratory disease.

25 36. A formulation according to any one of claims 1 to 35, in which the active particles comprise one or more active agents selected from β_2 -agonists, ipratropium bromide, steroids, cromones and leukotriene receptor antagonists.

37. A formulation according to claim 35, in which the active particles comprise a therapeutically active agent having systemic activity.

38. A formulation according to any one of claims 1 to 37, 5 in which the active particles comprise one or more agents selected from peptides, polypeptides, proteins and DNA fragments.

39. A formulation according to claim 38, in which the active particles comprise insulin.

10 40. A formulation according to any one of claims 1 to 39, which further comprises fine particles of an excipient material of aerodynamic diameter not more than 50 μm .

41. A formulation according to claim 40, in which the mass median aerodynamic diameter of the fine excipient particles 15 is not more than 15 μm .

42. A formulation according to claim 41, in which the mass median aerodynamic diameter of the excipient particles is not more than 10 μm .

43. A formulation according to any one of claims 40 to 42, 20 which includes the fine excipient particles in an amount of not less than 4% by weight, based on the total weight of the formulation.

44. A formulation according to any one of claims 40 to 43, including fine excipient particles in an amount of up to 25 20% by weight, based on the total weight of the formulation.

45. A formulation according to claim 44, in which the fine excipient particles are present in an amount of up to 15% by weight, based on the total weight of the formulation.

46. A formulation according to any one of claims 40 to 45, in which the fine excipient particles are of dextrose or lactose.

47. A formulation according to claim 46, in which the fine excipient particles are of lactose.

48. A formulation according to any one of claims 40 to 47, in which the carrier particles and the fine excipient particles are of the same material.

49. A formulation according to any one of claims 40 to 47, comprising up to 20% by weight fine excipient particles and up to 10% by weight additive material, based on the total weight of the formulation.

50. A formulation according to any one of claims 1 to 49, which comprises up to 10% by weight additive material, based on the total weight of the formulation.

51. A formulation according to any preceding claim, which comprises up to 5% by weight additive material, based on the total weight of the formulation.

52. A formulation for use in a dry powder inhaler, comprising more than 5%, and preferably more than 10% by weight, based on the total weight of the formulation, of particles of aerodynamic diameter less than 20 μm , the formulation having a flowability index of 12mm or less.

53. A formulation for use in an inhaler device, comprising:

from 5 to 90% by weight carrier particles having a diameter of at least 50 μm and a mass median diameter of at least 175 μm ;

from 0.01 to 90% by weight of a therapeutically active agent;

from 0.01 to 50% by weight of an additive material which is able to promote release of the active material on actuation of the inhaler device;

in each case, by weight, based on the total weight of 5 the carrier particles, active agent and additive material.

54. A formulation according to claim 53, which further comprises particles of a fine excipient material in an amount of not more than 50% by weight, based on the total weight of the formulation.

10 55. A formulation according to claim 53, in which the carrier particles are present in an amount not exceeding 70% by weight, based on the total weight of the formulation.

56. A formulation according to any one of claims 53 to 55 15 in which the total content of therapeutically active agent, additive material and, if present, fine excipient is at least 10% by weight based on the total weight of the formulation.

57. A formulation according to claim 56, in which the 20 total content of therapeutically active agent, additive material and, if present, fine excipient particles, is at least 20% by weight, based on the total weight of the formulation.

58. A formulation substantially as described herein.

25 59. A formulation substantially as described in any of Examples 1 to 18.

60. An inhaler device comprising a formulation according to any one of claims 1 to 59.

61. A device according to claim 60, which is a dry powder 30 inhaler.

62. A device according to claim 60, which is a pressurised metered dose inhaler.

63. A method of manufacturing a formulation according to any one of claims 1 to 59, comprising mixing the additive 5 material with the carrier particles and the active particles.

64. A method according to claim 63, in which the additive material is mixed with fine excipient material before mixing with the carrier particles and the active particles.

10 65. The use of fissured carrier particles of mass median diameter of at least 175 μ m in combination with an additive material to increase the fine particle fraction obtainable from a formulation for an inhaler device.

1/4




Figure 1

2/4




Figure 2

3/4




Figure 3

4/4




Figure 4

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 October 2001 (25.10.2001)

PCT

(10) International Publication Number
WO 01/78694 A3

(51) International Patent Classification⁷: A61K 9/72, 9/14

(21) International Application Number: PCT/GB01/01732

(22) International Filing Date: 17 April 2001 (17.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0009469.8 17 April 2000 (17.04.2000) GB
00113608.4 27 June 2000 (27.06.2000) EP

(71) Applicant (for all designated States except US): VECTURA LIMITED [GB/GB]; University of Bath Campus, Claverton Down, Bath BA2 7AY (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): STANIFORTH,



John, Nicholas [GB/GB]; High Trees, 170 Bloomfield Road, Bath BA2 2ST (GB). MORTON, David, Alexander, Vodden [GB/GB]; Linsley House, 2nd Floor Flat, Beechen Cliff Road, Bath BA2 4QR (GB). GILL, Rajbir [GB/GB]; 7 Oak Tree Close, Trowbridge, Wiltshire BA14 9BD (GB). BRAMBILLA, Gaetano [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). MUSA, Rossella [IT/IT]; Via Palermo, 26/A, I-43100 PARMA (IT). FERRARINI, Lorenzo [IT/IT]; Via Palermo, 26/A, I-43100 PARMA (IT).

(74) Agents: HUMPHREYS, Ceris, Anne et al.; Abel & Imray, 20 Red Lion Street, London WC1R 4PQ (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

[Continued on next page]

(54) Title: FORMULATIONS FOR USE IN INHALER DEVICES



WO 01/78694 A3

(57) Abstract: A formulation for an inhaler device comprises carrier particles having a diameter of at least 50 μm and a mass median diameter of at least 175 μm ; active particles; and additive material to which is able to promote release of the active particles from the carrier particles on actuation of the inhaler device. The formulation has excellent flowability even at relatively high fine particle contents.



(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(88) **Date of publication of the international search report:**
14 March 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

... *with international search report*

INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/GB 01/01732

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K9/72 A61K9/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 23485 A (CO ORDINATED DRUG DEV) 8 August 1996 (1996-08-08) cited in the application page 5, line 4 - line 16 page 10, line 10 - line 26 examples figure 1 claims 1,6,29,31 ---	1-65
Y	WO 96 02231 A (ASTA MEDICA AG) 1 February 1996 (1996-02-01) cited in the application page 3, line 25 -page 4, line 8 claims 1,3 examples --- -/-	1-65

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *S* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

10 October 2001

18/10/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL- 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Epskamp, S

1

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/01732

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 11666 A (CO ORDINATED DRUG DEV LTD) 4 May 1995 (1995-05-04) page 10, line 24 -page 11, line 6 page 12, line 2 -page 13, line 20 example 1 ---	52, 58-61
X	LUCAS P ET AL: "Protein deposition from dry powder inhalers: Fine particle multiplets as performance modifiers." PHARMACEUTICAL RESEARCH (NEW YORK), vol. 15, no. 4, April 1998 (1998-04), pages 562-569, XP001031594 ISSN: 0724-8741 page 563 ---	52, 58-61, 63
X	WO 93 11746 A (BOEHRINGER INGELHEIM KG) 24 June 1993 (1993-06-24) page 4, paragraph 3 -page 5 examples 1,2 ---	52, 58-61, 63
A	KAWASHIMA Y ET AL: "Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate." INTERNATIONAL JOURNAL OF PHARMACEUTICS (AMSTERDAM), vol. 172, no. 1-2, 15 October 1998 (1998-10-15), pages 179-188, XP001031579 ISSN: 0378-5173 paragraph '02.2!; figure 1; table 1 ---	6-12
P, X	WO 00 28979 A (SKYEPHARMA AG) 25 May 2000 (2000-05-25) page 9, line 16 - line 27 page 15, line 19 - line 32 examples 1,2 claim 22 -----	1-6, 13-15, 21, 22, 24-37, 40-42, 44-51, 58-61, 63

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 01/01732

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9623485	A 08-08-1996		AU 699131 B2 AU 4545696 A BG 101858 A BR 9607490 A CA 2211874 A1 CZ 9702443 A3 EE 9700176 A EP 0806938 A1 FI 973151 A WO 9623485 A1 HU 9802209 A2 JP 10513174 T NO 973502 A NZ 300654 A PL 321572 A1 SK 103697 A3 TR 9700722 T1 US 6153224 A ZA 9600721 A	26-11-1998 21-08-1996 30-04-1998 23-12-1997 08-08-1996 14-01-1998 16-02-1998 19-11-1997 30-09-1997 08-08-1996 01-02-1999 15-12-1998 30-09-1997 25-02-1999 08-12-1997 14-01-1998 21-02-1998 28-11-2000 19-08-1996
WO 9602231	A 01-02-1996		DE 4425255 A1 AT 204160 T AU 703924 B2 AU 2886295 A BR 9508287 A CA 2195065 A1 CN 1156960 A CZ 9700126 A3 DE 59509518 D1 WO 9602231 A1 EP 0771189 A1 FI 970164 A HR 950403 A1 HU 76807 A2 IL 114596 A JP 3011770 B2 JP 10502647 T NO 970068 A NZ 289117 A PL 318649 A1 RU 2140260 C1 SK 5697 A3 TR 960058 A2 US 6284287 B1 ZA 9505892 A	18-01-1996 15-09-2001 01-04-1999 16-02-1996 21-07-1998 01-02-1996 13-08-1997 18-02-1998 20-09-2001 01-02-1996 07-05-1997 15-01-1997 31-10-1997 28-11-1997 29-02-2000 21-02-2000 10-03-1998 08-01-1997 26-06-1998 07-07-1997 27-10-1999 04-06-1997 21-06-1996 04-09-2001 19-02-1996
WO 9511666	A 04-05-1995		AU 706986 B2 AU 7998194 A CA 2174767 A1 DE 69426459 D1 DE 69426459 T2 EP 0725624 A1 ES 2153864 T3 WO 9511666 A1 JP 9507049 T US 6221338 B1	01-07-1999 22-05-1995 04-05-1995 25-01-2001 23-08-2001 14-08-1996 16-03-2001 04-05-1995 15-07-1997 24-04-2001
WO 9311746	A 24-06-1993		DE 4140689 A1	17-06-1993

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 01/01732

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9311746	A	AT	164060 T	15-04-1998
		AU	3085492 A	19-07-1993
		CA	2125685 A1	24-06-1993
		DE	59209244 D1	23-04-1998
		DK	663815 T3	07-10-1998
		WO	9311746 A1	24-06-1993
		EP	0663815 A1	26-07-1995
		ES	2116353 T3	16-07-1998
		GR	3026516 T3	31-07-1998
		JP	8501056 T	06-02-1996
		NZ	246047 A	24-03-1997
		US	5478578 A	26-12-1995
WO 0028979	A 25-05-2000	AU	6457899 A	05-06-2000
		WO	0028979 A1	25-05-2000
		EP	1131059 A1	12-09-2001
		NO	20012346 A	26-06-2001

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.